We will attend DCAT week 2022

Pleased to announce that ICROM team will attend DCAT week 2022 in New York, March 21-24 We are very excited, after two years of on-line events, to finally attend the live event in New York and we look forward to meeting our customers and business partners at our suite 406 @InterContinental Barclay Hotel. To schedule...

A new Clinical Scale API Plant

Additional work in progress at ICROM! We are glad to start 2022 announcing the construction of our new Clinical Scale API Plant. Thanks to Manufacturing Chemist to talk about this important milestone for our company. To read the full article: https://www.manufacturingchemist.com/news/article_page/Icrom_to_boost_customer_clinical_projects_with_new_Clinical_Scale_API_Plant/198415

Icrom: one of the top 10 CMO companies in Europe 2021.

Pharma Tech Outlook interviewed our CEO Pierfrancesco Morosini, following the important award assigned to Icrom as one of the top 10 CMO companies in Europe 2021. “We offer CDMO capabilities and services from grams to tons under GMP regulations and use modern technologies and state of the art equipment in compliance with the most-strict regulatory requirements”. Dr. Morosini...

A new alliance: ICROM and PolyCrystalLine

THE TWO COMPANIESIcrom and PolyCrystalLine SpA have announced their strategic and exclusive partnership to provide integrated solutions for chemical development and custom manufacturing of APIs. The two Italian companies will offer their clients a high-tech, integrated full-service to handle challenging projects requiring various skills and technologies, by merging their expertise in research, chemical development, set...

A new strategic partnership with NerPharMa – Part of NMS Group

We are proud to announce our new strategic partnership with NerPharMa – Part of NMS Group, a veteran CDMO with a specialisation in oncology small molecule drug manufacture. The aim of our alliance is to cooperate on commercial production of High Potent drugs and ADC-Payload. Together we wil offer API development and formulated drug production...